About 61,235 results

ALLMedicine™ Multiple Sclerosis Center

Research & Reviews  20,267 results

Initial experience using the Axonics sacral neuromodulation system in patients with mul...
Neurourology and Urodynamics; Chen A, Kapur A et. al.

May 18th, 2022 - Sacral neuromodulation (SNM) is third-line therapy approved for urge urinary incontinence (UUI) and urgency, and nonobstructive urinary retention. Multiple sclerosis (MS) patients often suffer from neurogenic lower urinary tract dysfunction (NLUTD...

Neuromodulation for lower urinary tract symptoms in special populations.
Neurourology and Urodynamics; Wang CN, Chung DE

May 18th, 2022 - Discuss the efficacy, safety, and future directions of neuromodulation in special populations of patients with neurological conditions. A literature review was done to find meta-analyses, review articles, studies, and case reports of the use of ne...

Opportunities and challenges: mesenchymal stem cells in the treatment of multiple scler...
The International Journal of Neuroscience; Zhang Y, Gu J et. al.

May 18th, 2022 - Multiple sclerosis (MS) was once considered an untreatable disease. Through years of research, many drugs have been discovered and are widely used for the treatment of MS. However, the current treatment can only alleviate the clinical symptoms of ...

Effectiveness and Safety of Early High-Efficacy Versus Escalation Therapy in Relapsing-...
Clinical Neuropharmacology; Rojas JI, Patrucco L et. al.

May 18th, 2022 - Escalation (ES) and early high-efficacy (EHE) therapies have been the main treatment strategies adopted in multiple sclerosis (MS) in recent years. The aim of this study was to compare the effectiveness and safety of EHE versus ES strategies in MS...

Effects and optimal dosage of resistance training on strength, functional capacity, bal...
Disability and Rehabilitation; Andreu-Caravaca L, Ramos-Campo DJ et. al.

May 18th, 2022 - To analyze the effectiveness of resistance training programs (RTP) on strength, functional capacity, balance, general health perception, and fatigue for people with Multiple Sclerosis (MS) and to determine the most effective dose of RTP in this po...

see more →

Guidelines  15 results

Vision Problems in Multiple Sclerosis.
Archives of Physical Medicine and Rehabilitation; Costa SL, Pandey K et. al.

Sep 29th, 2020 - Vision Problems in Multiple Sclerosis.|2020|Costa SL,Pandey K,Hrdina J,Rondon M,Devos H,|

Serum neurofilament light as a biomarker in progressive multiple sclerosis.
Neurology Kapoor R, Smith KE et. al.

Jul 18th, 2020 - There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome the limitations of traditional imaging outcomes...

Practical Sleep Information for People With Multiple Sclerosis.
Archives of Physical Medicine and Rehabilitation; Siengsukon C, Karahan AY et. al.

May 14th, 2020 - Practical Sleep Information for People With Multiple Sclerosis.|2020|Siengsukon C,Karahan AY,Strober L,|

Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis...
Multiple Sclerosis and Related Disorders; Lebrun C, Vukusic S et. al.

Jun 5th, 2019 - To establish recommendations on immunization for patients with multiple sclerosis (MS) BACKGROUND: Vaccines have been suspected in the past to trigger MS and relapses. With the extension of the immunoactive treatment arsenal, other concerns have b...

ESPEN guideline clinical nutrition in neurology.
Clinical Nutrition (Edinburgh, Scotland); Burgos R, Bretón I et. al.

Dec 25th, 2017 - Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may...

see more →

Drugs  380 results see all →

Clinicaltrials.gov  869 results

Tolebrutinib, a Brain-penetrant Bruton s Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

May 13th, 2022 - Study Description: The primary goal of this protocol is to test whether 48 weeks of treatment with tolebrutinib, an investigational, orally available, brain-penetrant, Bruton s tyrosine kinase (BTK) inhibitor, affects an imaging marker (the parama...

Pathological Basis of MRI Signal Changes in Multiple Sclerosis

May 13th, 2022 - Objective: The goal of this protocol is to understand how the pathology of multiple sclerosis (MS) relates to its evolution over time as observed through neuroradiological, clinical, and biological data collection in vivo. Study population: This s...

Uveitis/Intraocular Inflammatory Disease Biobank (iBank)

May 13th, 2022 - Uveitis refers to a large group of intraocular inflammatory diseases that can cause devastating visual loss in adults and children. This study establishes a clinical database and biospecimen repository for the identification of novel factors relev...

Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)

May 13th, 2022 - The objective of this study is to examine the risk factors and natural course of JCV infection and progressive multifocal leukoencephalopathy (PML). PML is a devastating, demyelinating neurological disease affecting the brain of patients with a co...

Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis

May 13th, 2022 - B-cells have an important role in the pathogenesis of multiple sclerosis (MS). Ocrelizumab, a medication that targets B-cells have been found to be highly effective in stopping the disease activity in relapsing-remitting MS. The efficacy of ocreli...

see more →

News  2,910 results

Less Frequent Dosing With MS Drug Safe With No Loss of Efficacy

May 5th, 2022 - Most patients with relapsing-remitting multiple sclerosis (RRMS) who are stable on natalizumab (Tysabri, Biogen) administered once every 4 weeks (Q4W) may be able to safely switch to a once every 6 weeks (Q6W) dosing interval with no clinically me...

Using MRI to Track Cerebral Damage in Multiple Sclerosis

May 5th, 2022 - The study covered in this summary was published on medRxiv.org as a preprint and has not yet been peer reviewed. Key Takeaways Among patients with relapsing-remitting multiple sclerosis (RRMS), those who had a better clinical course were found to ...

Two MS Meds Tied to Higher COVID Rates

Apr 28th, 2022 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Patients taking ocrelizumab (Ocrevus) or fingolimod (Gilenya) for treat multiple sclerosis (MS) have higher rates of COVID-19 infection and hospit...

A hormone therapy shows favorable treatment satisfaction in menopausal women with MS

Apr 26th, 2022 - Key clinical point: Hormone therapy with Duavee®, containing conjugated estrogens ( 0. 45 mg ) and bazedoxifene ( 20 mg ), yielded a favorable study retention and treatment satisfaction in menopausal women with multiple sclerosis (MS).

Patients with multiple sclerosis at an increased risk for cardiovascular diseases

Apr 26th, 2022 - Key clinical point: Genetic liability to multiple sclerosis (MS) was associated with an increased risk for coronary artery disease (CAD), myocardial infarction (MI), heart failure (HF), all-cause stroke (AS), and any ischemic stroke (AIS), but not.

see more →

Patient Education  53 results see all →